Haleon plc filings document foreign private issuer disclosures for a global consumer health company whose American depositary shares trade under HLN. Form 6-K reports cover current information such as trading statements, ordinary-share repurchases for cancellation, total voting rights and capital, and annual general meeting poll results.
The filing record also includes debt-market disclosures, including listing particulars for the Euro Medium Term Note programme of Haleon UK Capital plc and Haleon Netherlands Capital B.V. guaranteed by Haleon. Governance and capital-structure disclosures address directors' remuneration, board elections, dividend approvals, special resolutions, ordinary shares, treasury shares, voting rights and shareholder notification thresholds.
On 11 July 2025, Haleon plc (LSE/NYSE: HLN) disclosed a TR-1 major shareholding notification from Wellington Management Group LLP. The investment manager’s aggregated interest fell from 5.87 % to 5.29 % of Haleon’s voting rights as of 10 July 2025, comprising 4.97 % held directly through ordinary shares (446.9 m votes) and 0.32 % via financial instruments (predominantly depository receipts and small equity swaps). The absolute position equals 475.6 m voting rights.
The reduction keeps Wellington above the critical UK 5 % disclosure threshold but signals incremental selling. No operational or earnings data are included; the filing is purely ownership-related.
Haleon plc (NYSE/LSE: HLN) has released unaudited historic pro-forma financials that restate 2023-2025 revenue under a new six-category reporting framework. The change, first signalled at the 1 May 2025 Capital Markets Day, splits the former “Digestive Health & Other” segment into two lines—Digestive Health and Therapeutic Skin Health & Other—and moves the Smokers Health franchise into Respiratory Health. Beginning with the Half-Year results on 31 July 2025, Haleon will report:
- Oral Health
- Vitamins, Minerals & Supplements (VMS)
- Pain Relief
- Respiratory Health
- Digestive Health
- Therapeutic Skin Health & Other
Key restated figures (FY 2024 vs FY 2023):
- Total revenue £11.23 bn, down 0.6%; organic revenue growth +5.0%
- Oral Health £3.31 bn (+5.6% reported, +9.6% organic) – strongest absolute contributor
- VMS £1.70 bn (+3.4% reported, +7.6% organic) – solid rebound from 0.9% organic in 2023
- Pain Relief £2.56 bn (-3.3% reported, +0.1% organic) – softness after 7.4% organic in 2023
- Respiratory Health £2.12 bn (-5.4% reported, +1.0% organic) – lapping strong 2023 cold/flu season
- Digestive Health £1.03 bn (+1.7% reported, +5.5% organic)
- Therapeutic Skin Health & Other £0.51 bn (-17.5% reported, +9.8% organic) – large FX/disposal drag
Q1 2025 restated revenue shows modest momentum: total £2.85 bn (-2.3% reported, +3.5% organic) with Oral Health (+3.0% reported) and Pain Relief (-0.2% reported, +2.6% organic) leading. Geographical splits are unchanged and no guidance is updated in this filing.
The recast enhances transparency around category-level trends and is intended to align external reporting with strategic growth priorities ahead of Haleon’s first standalone medium-term targets expected at H1 results.